Gland Pharma Ltd

(GLAND)

Director Qiyu Chen Exits Gland Pharma Board - 27 Aug, 2024

Qiyu Chen, a member of Gland Pharma's board of directors, will leave his position effective August 30 due to not receiving security clearance from the Ministry of Home Affairs.

Gland Pharma Reports Mixed Financial Performance - 15 Aug, 2024

Gland Pharma's shares rose nearly 2% to Rs. 2,007.95. The company reported a 16% YoY revenue increase but a 25.7% YoY decline in net profit. Mutual funds hold a 30% stake.

Gland Pharma Reports Mixed Q1 FY25 Results - 10 Aug, 2024

In Q1 FY25, Gland Pharma's revenue rose 16% year-over-year to Rs. 1,402 crore, while net profit fell 26% to Rs. 144 crore. Promoter stake decreased from 57.86% to 51.83%. Shares closed at Rs. 2,052.55, up 1.31%.

Gland Pharma Faces Earnings Decline and Analyst Downgrades - 07 Aug, 2024

Gland Pharma's Q1 results showed a 25.94% profit decline, leading to a 4% drop in shares. Analysts have mixed views, with Motilal Oswal maintaining a Buy rating at Rs 2,440, while Nomura downgraded to Reduce with a target of Rs 1,819.

Gland Pharma Reports Decline in Profit Despite Revenue Growth - 06 Aug, 2024

Gland Pharma's Q1 FY25 results show a 26% drop in net profit to ₹143.8 crore, while revenue increased 16% to ₹1,401 crore, driven by the US market. The company remains optimistic about future growth opportunities and is exploring strategic collaborations. Analysts had estimated a profit of ₹214 crore, indicating a miss on expectations.

USFDA Issues Observations to Gland Pharma's Facility - 05 Aug, 2024

The United States Food and Drug Administration (USFDA) conducted a surprise inspection of Gland Pharma's Pashamylaram facility, resulting in three procedural 483 Observations. Shares of the company fell by 1.75%.

Gland Pharma Approaches Ex-Date for First Ever Dividend - 04 Aug, 2024

Gland Pharma Ltd's board of directors recommended a final dividend of Rs 20 per equity share, with the record date set for August 16, 2024. The company is also set to announce its Q1 results on August 6, 2024. Gland Pharma's stock has gained 5.33% in the past week and delivered a robust 17.45% return over the last month.

Gland Pharma's Hyderabad Facility Receives 3 Observations from USFDA - 03 Aug, 2024

Gland Pharma's Hyderabad facility received three procedural observations from the US FDA during an inspection. The company will submit corrective and preventive actions within the required timeframe. The observations are not related to data integrity and are non-recurring. Gland Pharma reported a 145% rise in consolidated net profit at Rs 192.4 crore in Q4FY24, with revenue of Rs 1,537.5 crore. Shares closed marginally higher at Rs 2,126.

Gland Pharma Receives Three Observations from US FDA - 02 Aug, 2024

The US FDA issued a Form 483 with three observations to Gland Pharma after an unannounced inspection of its Pashamylaram facility. The observations are procedural and not related to data integrity, and the company will submit corrective actions within the stipulated period.